TB-500
A synthetic fragment of thymosin beta-4 studied for its role in actin regulation and cell migration, mechanisms tied to wound closure and reduced scar tissue formation in animal models.
Research status: Preclinical data dominates, concentrated in wound and vascular biology. Human evidence is limited to a small Phase 1 safety/dosing trial and an ophthalmic Phase II trial — not the tendon/ligament use case it's usually discussed for.
This page is a research-orientation summary, not a dosing guide. For anything beyond general background, read the primary literature or talk to a qualified clinician — specifics like amount, frequency, or administration aren't something we publish here.
Selected references
- Expert Opinion on Biological Therapy · 2012 Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications
- Annals of the New York Academy of Sciences · 2010 A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers
- Journal of Investigative Dermatology · 1999 Thymosin beta4 accelerates wound healing
- Clinical Ophthalmology · 2015 Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial
- Nature · 2004 Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair
Curated from published literature for research orientation. Not an exhaustive review, and not a substitute for reading primary sources.
Related in Healing